American Society of Hirudotherapy

Hirudin

The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Hirudin7 kDa
Molecular weight (kilodaltons) of Hirudin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Clinical and regulatory evidence (FDA-approved derived drug)
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding · Allergy / anaphylaxis

Clinical translation limit

Hirudin's direct thrombin binding in vitro and in animal models does NOT establish therapeutic efficacy of whole medicinal-leech therapy for any indication outside FDA-cleared microsurgical flap salvage (K040187). Pharmaceutical use of natural hirudin is rare; FDA-approved recombinant analogs (lepirudin, desirudin) and the synthetic analog bivalirudin are separate drugs with their own clinical evidence base.

Molecular structure drawn as tubes: human thrombin (heavy chain orange, light chain green) with leech hirudin (blue-violet) bound along its surface.
Hirudin (variant 2, Hirudo medicinalis) bound to human α-thrombin: the refined crystal structure of the hirudin–thrombin complex (PDB 4HTC, X-ray diffraction). Source: PDBe, EMBL-EBI — PDB 4HTC · PDBe public data (public domain)

Molecular Profile

Category
Anticoagulant
Evidence tier
Tier A — FDA-approved derivative
Molecular weight
7,000 Da
Source species
Hirudo medicinalis
Discovered
1884 · John Berry Haycraft (University of Edinburgh)
PubChem CID
258116129704
PDB structures
1HRT4HTC1HUT
Derived FDA-approved drug
Lepirudin (Refludan), Desirudin (Iprivask), Bivalirudin (Angiomax)

Biological Targets

  • → thrombin (Factor IIa)

Key Citations

  1. Haycraft JB (1884), Proc R Soc Lond
  2. Markwardt F (1957), Hoppe-Seylers Z Physiol Chem
  3. Stone SR, Hofsteenge J (1986), Biochemistry · PMID 3768302

Related Anticoagulant Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.